Latest & greatest articles for breast cancer screening

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on breast cancer screening or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on breast cancer screening and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for breast cancer screening

1. Screening for Breast Cancer in Average-Risk Women Full Text available with Trip Pro

reviews showed that women aged 39 to 49 years derived the lowest absolute benefit in terms of deaths prevented ( , ) ( ). Observational studies showed larger relative reductions in breast cancer mortality ( ). Evidence from RCTs (fair quality) and observational studies (poor quality) did not show a reduction in the incidence of advanced disease with breast cancer screening in women aged 39 to 49 years (pooled results from 4 RCTs: relative risk, 0.98 [95% CI, 0.74 to 1.37]) ( ). Screening intervals (...) diagnostic accuracy characteristics regarding cancer detection, false-positive results, recalls, and biopsy rates. Compared with conventional mammography, DBT seems to reduce recall rates and increase cancer detection ( ). The effect of these more sensitive imaging methods on the spectrum of detected disease and associated screening benefits and harms, including overdiagnosis, is not known. Alternative or Adjunctive Tests to Screening Mammography in Women Who Have Dense Breasts Increased breast density

2019 American College of Physicians

2. Breast Cancer Risk Assessment and Screening in Average-Risk Women

between the ages of 10 years and 14 years appear to be at greatest risk of future development of breast cancer. General Considerations for Screening The goal of screening for cancer is to detect preclinical disease in healthy, asymptomatic patients to prevent adverse outcomes, improve survival, and avoid the need for more intensive treatments. Screening tests have both benefits (eg, improved health outcomes) and adverse consequences (eg, cost, anxiety, inconvenience, false-positive results, and other (...) test-specific harms such as overdiagnosis and overtreatment). Breast self-examination, breast self-awareness, clinical breast examination, and mammography all have been used alone or in combination to screen for breast cancer. In general, more intensive screening detects more disease. Screening intensity can be increased by combining multiple screening methods, extending screening over a wider age range, or repeating the screening test more frequently. However, more frequent use of the same

2017 American College of Obstetricians and Gynecologists

3. Breast Cancer Screening

also benefit from supplemental screening. The recommendations for supplemental screening for women at intermediate risk of breast cancer, including those with a personal history of breast cancer, a history of lobular carcinoma in situ or ADH, those with an intermediate family history and a lifetime risk of 15% to 20%, or women with dense breasts continues to be an area of debate [47]. Mammography and DBT Annual screening mammography is recommended for women with biopsy-proven lobular neoplasia (...) and with IV contrast Usually Not Appropriate O MRI breast without IV contrast Usually Not Appropriate O FDG-PEM Usually Not Appropriate ???? Tc-99m sestamibi MBI Usually Not Appropriate ??? Variant 2: Breast cancer screening. Intermediate-risk women: women with personal history of breast cancer, lobular neoplasia, atypical ductal hyperplasia, or 15% to 20% lifetime risk of breast cancer. Procedure Appropriateness Category Relative Radiation Level Mammography screening Usually Appropriate ?? Digital breast

2017 American College of Radiology

4. Recommendations on screening for breast cancer in women 40-74 years of age who are not at increased risk

Recommendations on screening for breast cancer in women 40-74 years of age who are not at increased risk Recommendations on screening for breast cancer in women aged 40–74 years who are not at increased risk for breast cancer | CMAJ Main menu User menu Search Search for this keyword Search for this keyword Guideline Recommendations on screening for breast cancer in women aged 40–74 years who are not at increased risk for breast cancer Scott Klarenbach , Nicki Sims-Jones , Gabriela Lewin (...) POINTS Low-certainty evidence indicates that screening for breast cancer with mammography results in a modest reduction in breast cancer mortality for women aged 40 to 74 years; the absolute benefit is lowest for women younger than 50 years. Screening may lead to overdiagnosis, resulting in unnecessary treatment of cancer that would not have caused harm in a woman’s lifetime and false-positive results that can lead to both physical and psychological consequences; overdiagnosis and false-positives

2018 Canadian Task Force on Preventive Health Care

5. Magnetic Resonance Imaging as an Adjunct to Mammography for Breast Cancer Screening in Women at Less Than High Risk for Breast Cancer

Magnetic Resonance Imaging as an Adjunct to Mammography for Breast Cancer Screening in Women at Less Than High Risk for Breast Cancer Magnetic Resonance Imaging as an Adjunct to Mammography for Breast Cancer Screening in Women at Less Than High Risk for Breast Cancer - Health Quality Ontario (HQO) Let's make our health system healthier Open Menu Quick Links Search Search A A A Evidence to Improve Care Share: Magnetic Resonance Imaging as an Adjunct to Mammography for Breast Cancer Screening (...) in Women at Less Than High Risk for Breast Cancer Ontario Health Technology Advisory Committee Recommendation The Ontario Health Technology Advisory Committee recommends against publicly funding screening breast magnetic resonance imaging (MRI) as an adjunct to screening mammography for women who are at less than high risk for breast cancer and who have no personal history of breast cancer Breast cancer is the most common cancer among Canadian women. The most common form of screening for breast cancer

2017 Health Quality Ontario

6. Breast Cancer Screening

including them at this time. Chest radiation therapy for treatment of Hodgkin’s disease between ages 10 and 30 Annual screening with both mammogram and MRI starting: • 8 years post-radiation therapy, but • Not before age 25 • Breast biopsy with suspicious results: atypical hyperplasia or lobular neoplasia (lobular carcinoma in situ) • Breast cancer at age 50 or older Under 40: Consult Oncology to discuss type of screening and when to initiate. 40 or over: Annual screening with mammogram starting now (...) Breast Cancer Screening © 1996 Kaiser Foundation Health Plan of Washington. All rights reserved. 1 Breast Cancer Risk Assessment and Screening Guideline Major Changes as of September 2017 2 Background and Principles 2 Risk Assessment 3 Screening Recommendations Based on Risk Assessment 4 Shared Decision Making for Women at Average Risk 5 Screening Tests and Exams 7 Referral to Genetics or Oncology 8 Evidence Summary and References 8 Guideline Development Process and Team 9 Appendix 1. Breast

2017 Kaiser Permanente Clinical Guidelines

8. Prevention and Screening in BRCA Mutation Carriers and Other Breast/Ovarian Hereditary Cancer Syndromes

. Importantly, accurate and reliable risk estimation and strati?cation for malignancy risk is highly problematicformostofthegenesidenti?edinthesepanels[49]. The following genes might have moderate- to high- penetrance germline mutations for breast or ovarian cancer: p53, PTEN, CDH1, PALB2, CHEK2, ATM, RAD51C, STK11, RAD51D, BRIP1, MLH1, MSH2, MSH6 and PMS2. Prevention and screening strategies for these mutations are summarised in Table 1—due to limited research in individuals harbouring these mutations (...) Prevention and Screening in BRCA Mutation Carriers and Other Breast/Ovarian Hereditary Cancer Syndromes PreventionandscreeninginBRCAmutationcarriersand otherbreast/ovarianhereditarycancersyndromes: ESMOClinicalPracticeGuidelinesforcancerprevention andscreening † S.Paluch-Shimon 1 ,F.Cardoso 2 ,C.Sessa 3 ,J.Balmana 4 ,M.J.Cardoso 2 ,F.Gilbert 5 &E.Senkus 6 , onbehalfoftheESMOGuidelinesCommittee * 1 DivisionofOncologyandtheDrPinchasBorensteinTalpiotMedicalLeadershipProgram,ShebaMedicalCenter

2017 European Society for Medical Oncology

9. Breast cancer screening

choose to begin biennial screening between the ages of 40 and 49 years. • For women who are at average risk for breast cancer , most of the benefit of mammography results from biennial screening during ages 50 to 74 years. Of all of the age groups, women aged 60 to 69 2016 5. Mammography in combination with breast ultrasonography versus mammography for breast cancer screening in women at average risk. BACKGROUND: Breast cancer is the most common malignant disease diagnosed in women worldwide (...) Breast cancer screening Top results for breast cancer screening - Trip Database or use your Google+ account Turning Research Into Practice ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might

2018 Trip Latest and Greatest

10. Improvement in risk prediction, early detection and prevention of breast cancer in the NHS Breast Screening Programme and family history clinics: a dual cohort study Full Text available with Trip Pro

Improvement in risk prediction, early detection and prevention of breast cancer in the NHS Breast Screening Programme and family history clinics: a dual cohort study Improvement in risk prediction, early detection and prevention of breast cancer in the NHS Breast Screening Programme and family history clinics:a dual cohort study Journals Library An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you requested could

2016 NIHR HTA programme

11. Screening for Breast Cancer in Women at Average Risk*

of a woman's lifetime. ACS selected the Duke University Evidence Synthesis Group to conduct an independent systematic evidence review after a response to a request for proposals, and commissioned the Breast Cancer Surveillance Consortium (BCSC) to update previously published analyses related to the screening interval and outcomes. The ACS Surveillance and Health Services Research Program provided supplementary data on disease burden using data from the Surveillance, Epidemiology, and End Results (SEER (...) Screening for Breast Cancer in Women at Average Risk* Screening for Breast Cancer in Women at Average Risk | National Guideline Clearinghouse success fail JUL Aug 12 2018 2019 30 Sep 2016 - 13 Jul 2018 COLLECTED BY Organization: Formed in 2009, the Archive Team (not to be confused with the archive.org Archive-It Team) is a rogue archivist collective dedicated to saving copies of rapidly dying or deleted websites for the sake of history and digital heritage. The group is 100% composed

2016 National Guideline Clearinghouse (partial archive)

12. Breast Cancer Screening (PDQ®): Health Professional Version

System. Recall rate was lower with DBT than with FFDM (7.9% vs. 10.9%; 95% confidence interval [CI], 0.77–0.85), but there was no difference in the rates of biopsy or the detection of benign or malignant disease.[ ] Characteristics of Cancers Detected by Breast Imaging Regardless of stage, nodal status, and tumor size, screen-detected cancers have a better prognosis than those diagnosed outside of screening.[ ] This suggests that they are biologically less lethal (perhaps slower growing and less (...) of Effect : Between 20% and 50% of screen-detected cancers represent overdiagnosis based on patient age, life expectancy, and tumor type (ductal carcinoma in situ and/or invasive).[ , ] These estimates are based on two imperfect analytic methods:[ , ] Long-term follow-up of RCTs of screening. The calculation of excess incidence in large screening programs.[ , ] Study Design : RCTs, descriptive, population-based comparisons, autopsy series, and series of mammary reduction specimens. False Positives

2018 PDQ - NCI's Comprehensive Cancer Database

13. Magnetic resonance imaging as an adjunct to mammography for breast cancer screening in women atless than high risk for breast cancer: a health technology assessment

; 16(20). 2016 Authors' conclusions It remains uncertain if the use of adjunct screening breast MRI in women at less than high risk (average or higher than average risk) for breast cancer will reduce breast cancer–related mortality without significant increases in unnecessary follow-up testing and treatment. Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Breast Neoplasms; Humans; Magnetic Resonance Imaging; Mammography; Risk Language Published English Country (...) Magnetic resonance imaging as an adjunct to mammography for breast cancer screening in women atless than high risk for breast cancer: a health technology assessment Magnetic resonance imaging as an adjunct to mammography for breast cancer screening in women at less than high risk for breast cancer: a health technology assessment Magnetic resonance imaging as an adjunct to mammography for breast cancer screening in women at less than high risk for breast cancer: a health technology assessment

2017 Health Technology Assessment (HTA) Database.

14. Recommendations on screening for breast cancer in average-risk women aged 40?74 years

over precisely which screening services should be provided and to whom, these methods are frequently used in contemporary practice. 2–4 Outcomes of screening for breast cancer such as tumour detection and mortality must be put into context of the harms and costs of false - positive results, overdiagnosis and overtreatment. Consideration of benefi ts, harms and costs is complicated by variations in risk factors and in the types and stages of cancer. Any positive result from screening has emo- tional (...) Care (2001). 5,6 The absence of current Canadian recommendations, the recent contro- versy over the best way to screen for breast cancer among women at average risk of the disease, 7,8 the availability of new technologies such as magnetic resonance imaging (MRI) and a recent review of the evidence 9 were the basis for selecting this topic for an update by the revitalized Canadian Task Force on Preventive Health Care. Recommendations are presented for the use of mammography, MRI, breast self

2012 CPG Infobase

15. Digital Tomosynthesis for the Screening and Diagnosis of Breast Cancer: Diagnostic Accuracy, Cost-Effectiveness, and Guidelines

Digital Tomosynthesis for the Screening and Diagnosis of Breast Cancer: Diagnostic Accuracy, Cost-Effectiveness, and Guidelines Digital Tomosynthesis for the Screening and Diagnosis of Breast Cancer: Diagnostic Accuracy, Cost-Effectiveness, and Guidelines | CADTH.ca Find the information you need Digital Tomosynthesis for the Screening and Diagnosis of Breast Cancer: Diagnostic Accuracy, Cost-Effectiveness, and Guidelines Digital Tomosynthesis for the Screening and Diagnosis of Breast Cancer (...) for breast cancer diagnosis? What is the comparative clinical effectiveness of synthetic 2D mammography compared with conventional 2D digital mammography obtained with 3D digital tomosynthesis? What is the cost effectiveness of 3D digital tomosynthesis with or without 2D mammography compared with 2D mammography alone for breast cancer screening or diagnosis? What are the evidence-based guidelines regarding the use of 3D digital tomosynthesis for breast cancer screening and diagnosis? Key Message Seven

2019 Canadian Agency for Drugs and Technologies in Health - Rapid Review

16. Digital breast tomosynthesis for breast cancer diagnosis and screening

improve patient management and health outcomes? Are there any safety issues associated with the use of DBT? Have definitive patient selection criteria been established for DBT for screening or diagnosis of breast cancer? Final publication URL The report may be purchased from: Indexing Status Subject indexing assigned by CRD MeSH Breast Neoplasms; Humans; Mammography; Tomography, X-Ray Language Published English Country of organisation United States English summary An English language summary (...) Digital breast tomosynthesis for breast cancer diagnosis and screening Digital breast tomosynthesis for breast cancer diagnosis and screening Digital breast tomosynthesis for breast cancer diagnosis and screening HAYES, Inc Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation HAYES, Inc. Digital breast tomosynthesis for breast cancer diagnosis and screening. Lansdale

2017 Health Technology Assessment (HTA) Database.

17. Cancer Screening: Interventions Engaging Community Health Workers – Breast Cancer

or 42 CommGuideCancerMCIPsycINFO 1. (mass screening or multiphasic screening or screen or screened or screening or "early detection of cancer").mp. 2. ((neoplasm* or ductal breast carcinoma* or "hereditary breast and ovarian cancer syndrome") and (diagnosis or prevention)).mp. [mp=title, abstract, heading word, table of contents, key concepts, original title, tests & measures] 3. ((adenoma* or neoplasia or cancer* or neoplasm* or tumo?r* or carcinoma* or adenocarcinoma*) and (breast or cervical (...) or screening).ti,ab. or "early detection of cancer"/ 20. (neoplasms/ or breast neoplasms/ or colorectal neoplasms/ or uterine cervical neoplasms/ or carcinoma, ductal, breast/ or "hereditary breast and ovarian cancer syndrome"/ or inflammatory breast neoplasms/ or colonic neoplasms/ or rectal neoplasms/) and (di or pc).fs. 21. ((adenoma* or neoplasia or cancer* or neoplasm* or tumo?r* or carcinoma* or adenocarcinoma*) and (breast or cervical or cervix or colon or colorectal or crc)).ti,ab. 22. 20 or 21 23

2020 Community Preventive Services Task Force

18. Ultrasound as an Adjunct to Mammography for Breast Cancer Screening

also recognized that the population of high-risk women is very small, with a high burden of disease, and that this technology may be particularly helpful in women who have a contraindication to MRI, the current standard of care. Ultrasound as an Adjunct to Mammography for Breast Cancer Screening: OHTAC Recommendation. July 2016; pp. 1–4 2 Decision Determinants for Ultrasound as an Adjunct to Mammography for Breast Cancer Screening Decision Criteria Subcriteria Decision Determinants Considerations (...) of the disease. Need How large is the need for this health technology/intervention? Women at average risk for developing breast cancer currently only receive mammography screening for breast cancer. Mammography screening is not perfect, and therefore a number of these women may have their cancers missed by mammography due to factors such as dense breasts and younger age. Currently, 1.15 million women in Ontario aged 50 to 74 years are screened with mammography annually. Women at high risk for breast cancer

2016 Health Quality Ontario

19. Two-view digital breast tomosynthesis versus digital mammography in a population-based breast cancer screening programme (To-Be): a randomised, controlled trial Full Text available with Trip Pro

Two-view digital breast tomosynthesis versus digital mammography in a population-based breast cancer screening programme (To-Be): a randomised, controlled trial Digital breast tomosynthesis is an advancement of mammography, and has the potential to overcome limitations of standard digital mammography. This study aimed to compare first-generation digital breast tomo-synthesis including two-dimensional (2D) synthetic mammograms versus digital mammography in a population-based screening (...) cancer, stratified by screening technique (ie, digital breast tomosynthesis and digital mammography). A log-binomial regression model was used to estimate the efficacy of digital breast tomosynthesis versus digital mammography, defined as the crude risk ratios (RRs) with 95% CIs for screen-detected breast cancer for women screened during the recruitment period. A per-protocol approach was used in the analyses. This trial is registered at ClinicalTrials.gov, number NCT02835625, and is closed

2019 EvidenceUpdates

20. Concurrent versus Sequential Digital Mammography and MRI for Breast Cancer Screening in High-Risk Patients

Evaluations 1. Ahern CH, Shih YC, Dong W, Parmigiani G, Shen Y. Cost-effectiveness of alternative strategies for integrating MRI into breast cancer screening for women at high risk. Br J Cancer [Internet]. 2014 Oct 14 [cited 2015 May 6];111(8):1542-51. Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4200098 PubMed: PM25137022 Guidelines and Recommendations 2. Institute for Clinical Systems Improvement (ICSI). Health Care Guideline: Diagnosis of Breast Disease 14 th edition [Inetrnet (...) Concurrent versus Sequential Digital Mammography and MRI for Breast Cancer Screening in High-Risk Patients Disclaimer: The Rapid Response Service is an information service for those involved in planning and providing health care in Canada. Rapid responses are based on a limited literature search and are not comprehensive, systematic reviews. The intent is to provide a list of sources of the best evidence on the topic that CADTH could identify using all reasonable efforts within the time allowed

2015 Canadian Agency for Drugs and Technologies in Health - Rapid Review